IT TOOK NEARLY three years to win presumptive workers’ compensation coverage for breast, cervical, and other cancers that ...

Medically reviewed by Qin Rao, MD Barrett's esophagus occurs when the lining of the esophagus, the tube that runs from the ...

A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors ...

Background: Neoadjuvant therapy is widely used for esophageal cancer (EC), but optimal treatment regimens and predictive factors for outcomes remain unclear. This study retrospectively analyzed data ...

Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive malignancies, with a 5-year survival rate of only 20%. Although some cancer ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...